CCM
INO icon

Camber Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Camber Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-20,833
Closed -$2.04M – 47
2015
Q1 		$2.04M Hold
20,833
– – 0.15% 36
2014
Q4 		$2.29M Hold
20,833
– – 0.15% 41
2014
Q3 		$2.46M Buy
+20,833
New +$2.6M 0.23% 37

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Camber Capital Management's INO Position: Q2 2015 in Review

Camber Capital Management sold out of Inovio Pharmaceuticals (INO) in Q2 2015, closing a stake of 20,833 shares — an estimated $2.04M sold.

Camber Capital Management first reported a position in INO in Q3 2014 and held it in 3 quarters. The position peaked at $2.46M in Q3 2014. 105 funds tracked by Wall St. Rank hold INO as of Q2 2015.

  • Camber Capital Management reported no remaining Inovio Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Camber Capital Management sold 20,833 Inovio Pharmaceuticals shares in Q2 2015, an estimated $2.04M.
  • Camber Capital Management first reported a position in Inovio Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • Camber Capital Management's Inovio Pharmaceuticals position peaked at $2.46M in Q3 2014.
  • 105 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2015.

Based on Camber Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.